Antisoma buys out Imperial Cancer stake in Cancer Therapeutics Ltd
This article was originally published in Clinica
Antisoma, the London-based biopharmaceuticals company which is developing an epithelially preferential contrast agent, has bought out its research partner's share in Cancer Therapeutics (CTL).
You may also be interested in...
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.